An open letter from Eli Lilly and Company warning of potential patient safety risks associated with tirzepatide compounded with vitamin B12

Eli Lilly found a significant impurity formed when tirzepatide is compounded with vitamin B12, notified the FDA, and urged patients and regulators to avoid or recall such untested combination products. This raises near-term regulatory and legal pressure on mass compounders, telehealth providers and medspas (increasing odds of FDA enforcement/recalls) while potentially curtailing illicit competition to Lilly’s approved Mounjaro and Zepbound products; monitor FDA recalls/enforcement and any litigation that could affect compounding businesses and sector reputations.

Analysis

Removing a durable grey-market supply stream would act like a hidden price-support for approved GLP-1s: conservatively, recapturing even ~10-20% of diversioned patient volume could lift branded makers’ realized pricing power and shorten time-to-revenue for new indications. Expect this to show up as improving mix (higher ASP per script) and lower incremental marketing spend per net new patient over 3–12 months, not instant revenue spikes.

A single high-profile adverse event tied to an unvetted combination remains the largest near-term tail risk: that can produce rapid regulatory escalations (recalls, expanded inspections) and class-action exposure that compresses shares for weeks and increases implied volatility for options. Conversely, a phased enforcement campaign that mostly shuts down mass-compounding without triggering major patient harm is a multi-quarter positive for capacity-constrained sterile injectables and the originator balance sheets.

Strategically, the market tends to over-penalize the originator for safety headlines while underpricing the structural benefit of reduced substitution. That asymmetry creates a time-limited window where volatility hedged exposure to a leading approved manufacturer offers asymmetric upside into the next 3–9 months as gray supply contracts and payers re-evaluate coverage patterns for authentic products.

Key Decisions for Investors

• LLY – 3–9 month bull-call spread: Buy 6–9 month LLY 5–10% OTM calls and sell a higher strike to fund (~1:3 intrinsic R/R if funded). Thesis: captures approval-market re-pricing as illicit supply contracts; risk = option premium (max loss). Trigger: scale in on >10% post-headline drawdown, cut if adverse regulatory recall announced.
• Pair trade – Long LLY / Short TDOC (equal $ notional) for 3–6 months: LLY benefits from reduced diversion; TDOC/telehealth peers are more exposed to reputational/regulatory flow and could see lower referral volumes. Risk: Teladoc may be insulated; cap losses to 8–12% by stops or buy protective calls.
• CTLT – 6–12 month long-call or outright buy: sterile injectable CDMO exposure to capture higher utilization and pricing power if compounding shuts down at scale. Risk/reward: high operational leverage to utilization; set stop at 20% from entry and target 30–50% upside.
• Volatility hedge if long LLY: buy 3–6 month protective puts (10–15% OTM) sized to limit drawdown from an adverse-event gap. Cost is insurance; payoff is rapid if an unexpected recall or litigation headline emerges.